Wilson Kirsty L, Xiang Sue D, Plebanski Magdalena
Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC Australia.
Front Microbiol. 2015 Feb 6;6:29. doi: 10.3389/fmicb.2015.00029. eCollection 2015.
The development of practical and flexible vaccines to target liver stage malaria parasites would benefit from an ability to induce high levels of CD8 T cells to minimal peptide epitopes. Herein we compare different adjuvant and carrier systems in a murine model for induction of interferon gamma (IFN-γ) producing CD8 T cells to the minimal immuno-dominant peptide epitope from the circumsporozoite protein (CSP) of Plasmodium berghei, pb9 (SYIPSAEKI, referred to as KI). Two pro-inflammatory adjuvants, Montanide and Poly I:C, and a non-classical, non-inflammatory nanoparticle based carrier (polystyrene nanoparticles, PSNPs), were compared side-by-side for their ability to induce potentially protective CD8 T cell responses after two immunizations. KI in Montanide (Montanide + KI) or covalently conjugated to PSNPs (PSNPs-KI) induced such high responses, whereas adjuvanting with Poly I:C or PSNPs without conjugation was ineffective. This result was consistent with an observed induction of an immunosuppressed environment by Poly I:C in the draining lymph node (dLN) 48 h post injection, which was reflected by increased frequencies of myeloid derived suppressor cells (MDSCs) and a proportion of inflammation reactive regulatory T cells (Treg) expressing the tumor necrosis factor receptor 2 (TNFR2), as well as decreased dendritic cell (DC) maturation. The other inflammatory adjuvant, Montanide, also promoted proportional increases in the TNFR2(+) Treg subpopulation, but not MDSCs, in the dLN. By contrast, injection with non-inflammatory PSNPs did not cause these changes. Induction of high CD8 T cell responses, using minimal peptide epitopes, can be achieved by non-inflammatory carrier nanoparticles, which in contrast to some conventional inflammatory adjuvants, do not expand either MDSCs or inflammation reactive Tregs at the site of priming.
开发针对肝期疟原虫的实用且灵活的疫苗,若能诱导高水平的CD8 T细胞针对最小肽表位,将会从中受益。在此,我们在小鼠模型中比较了不同的佐剂和载体系统,以诱导产生干扰素γ(IFN-γ)的CD8 T细胞针对来自伯氏疟原虫环子孢子蛋白(CSP)的最小免疫显性肽表位pb9(SYIPSAEKI,简称KI)。将两种促炎性佐剂Montanide和聚肌胞苷酸(Poly I:C),以及一种基于非经典、非炎性纳米颗粒的载体(聚苯乙烯纳米颗粒,PSNPs)进行了并排比较,以评估它们在两次免疫后诱导潜在保护性CD8 T细胞反应的能力。Montanide中的KI(Montanide + KI)或与PSNPs共价偶联的KI(PSNPs-KI)诱导了如此高的反应,而用Poly I:C或未偶联的PSNPs进行佐剂化则无效。这一结果与注射后48小时在引流淋巴结(dLN)中观察到的Poly I:C诱导的免疫抑制环境一致,这表现为髓源性抑制细胞(MDSC)频率增加以及一部分表达肿瘤坏死因子受体2(TNFR2)的炎症反应性调节性T细胞(Treg)比例增加,同时树突状细胞(DC)成熟度降低。另一种炎性佐剂Montanide也促进了dLN中TNFR2(+) Treg亚群比例的增加,但未促进MDSC增加。相比之下,注射非炎性PSNPs不会引起这些变化。使用最小肽表位诱导高CD8 T细胞反应可以通过非炎性载体纳米颗粒实现,与一些传统炎性佐剂相比,这些纳米颗粒在启动部位不会扩增MDSC或炎症反应性Treg。